← Issue №18/ week of Nov 1, 2026/Hepatology

Small-Intestinal Motility Interrelates With Fecal Microbiota, Metabolites and Metabolic Tissue Gene Expression in Metabolic Dysfunction-Associated Steatotic Liver Disease.

From GI Signals issue №18: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Hepatology prospective cohort · n=15 · Oct 30, 2026 · J Neurogastro Motil · IF 3.4

Small-Intestinal Motility Interrelates With Fecal Microbiota, Metabolites and Metabolic Tissue Gene Expression in Metabolic Dysfunction-Associated Steatotic Liver Disease.

Basic sciencemicrobiomebasic sciencetranslationalMASLD
Clinical takeawayNo clinical action yet: exploratory findings in humans linking small-intestinal motility to microbiota and metabolic tissue expression, requiring further investigation for causality and clinical relevance.
What it foundSmall-intestinal motility in MASLD patients correlated with fecal microbiota (Verrucomicrobia and Bacteroidetes phyla, 41 species), liver mRNA expression of CBS (FDR-P < 0.001), and adipose tissue mRNA expression of SCARB1 and SCD1 (FDR-P < 0.05).
ContextOpens a question on the interplay between small-intestinal motility, gut microbiota, and metabolic tissue expression in MASLD, a relationship not previously explored in humans.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Houttu V … Jonge CS · Journal of Neurogastroenterology and Motility · IF 3.4 · PubMed ↗Permalink
← Read the whole of issue №18 Every paper GI Signals surfaces gets a page like this one. All issues